Clinical Effectiveness of Intravitreal Therapy With Ranibizumab vs Aflibercept vs Bevacizumab for Macular Edema Secondary to Central Retinal Vein Occlusion: A Randomized Clinical Trial.
Hykin P, Prevost AT, Vasconcelos JC, Murphy C, Kelly J, Ramu J, Hounsome B, Yang Y, Harding SP, Lotery A, Chakravarthy U, Sivaprasad S.
Main finding: Mean change in vision were similar with Aflibercept and Ranibizumab. in macular oedema due to CRVO. Vision change with Bevacizumab vs Ranibizumab was inconclusive.
Purpose: To determine whether intravitreal aflibercept or bevacizumab compared with ranibizumab results in a noninferior mean change in vision at 100 weeks for eyes with CRVO-related macular edema.
Study type: Randomized controlled trial.
Condition: Central retinal vein occlusion
Participants: ≥18 yo with macular oedema secondary to CRVO, BCVA 20/32-20/400, mean central subfield thickness ≥320 μm
n=463
Intervention:
Group 1: Intravitreal Ranibizumab 0.5mg q4weekly x 3 then PRN if retreatment criteriae met
Group 2: Intravitreal Aflibercept 2mg q4weekly x 3 then PRN if retreatment criteriae met
Group 3: Intravitreal Bevacizumab 1.25mg q4weekly x 3 then PRN if retreatment criteriae met
RAN
AFLI
BEV
BCVA gain (letters)
+12.5
+15.1
+9.8
Mean injections
11.8
10.0
11.5
Share This Article :
Please provide feedback on content published. Thank you.
Source Archive